Industry Payments and Prescribing Patterns of Pulmonary Hypertension Therapies in the United States.

IF 2.5 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Pulmonary Circulation Pub Date : 2026-03-08 eCollection Date: 2026-01-01 DOI:10.1002/pul2.70279

Elizabeth S Tarras, Anju Murayama, Inderjit Singh, Lina M Freeman, Hinari Kugo, Deborah C Marshall

引用次数: 0

Abstract

This study analyzed the US Open Payments and Medicare Part D databases from 2014 to 2022 to assess associations between industry-physician payments and PAH therapy prescribing. Among 5502 pulmonologist-, cardiologist- and pediatrician-prescribers of PAH therapies, drug-specific industry payments were associated with dose-response increases in Medicare spending.

查看原文本刊更多论文

美国肺动脉高压治疗的行业支付和处方模式。

本研究分析了2014年至2022年美国开放支付和医疗保险D部分数据库，以评估行业医生支付与多环芳烃治疗处方之间的关系。在5502名肺病专家、心脏病专家和儿科医生的多环芳烃治疗处方中，特定药物的行业支付与医疗保险支出的剂量反应增加有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pulmonary Circulation Medicine-Pulmonary and Respiratory Medicine

CiteScore

4.20

自引率

11.50%

发文量

153

审稿时长

15 weeks

期刊介绍： Pulmonary Circulation''s main goal is to encourage basic, translational, and clinical research by investigators, physician-scientists, and clinicans, in the hope of increasing survival rates for pulmonary hypertension and other pulmonary vascular diseases worldwide, and developing new therapeutic approaches for the diseases. Freely available online, Pulmonary Circulation allows diverse knowledge of research, techniques, and case studies to reach a wide readership of specialists in order to improve patient care and treatment outcomes.